NCT00710970 - Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2012

Conditions

Urinary Bladder Neoplasms

Interventions

DRUG

Tamoxifen

Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.

Trial Locations (2)

77030

Baylor College Of Medicine, Houston

Unknown

San Camillo and Forlanini Hospitals, Rome